Business, energy, technology, markets and global industry news from Business News Today

Specialised Therapeutics

PharmaDeviceNews Specialised Therapeutics
A patient receives hospital-based infusion therapy as Australia’s PBS listing of Minjuvi expands access to a chemotherapy-free immunotherapy combination for adults with relapsed or refractory follicular lymphoma. Representative image.
Pharma & Biotech

Incyte’s Minjuvi gains Australian reimbursement after TGA follicular lymphoma registration

Australia has listed Minjuvi on the PBS for relapsed follicular lymphoma. See what the inMIND data and access terms mean.

Read More
Pharma & Biotech

Thailand approves NERLYNX for HER2+ breast cancer: Will it change relapse prevention?

NERLYNX launches in Thailand for HER2+ breast cancer. Find out how neratinib could reshape relapse prevention and treatment sequencing across Southeast Asia.

Read More